About the Company
allakos inc is a biotechnology company located in 7400 paseo padre pkwy, fremont, ca, united states.
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
Employees
124
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ALLK News
Here's Why Allakos Inc. (ALLK) is Poised for a Turnaround After Losing -61.36% in 4 Weeks
Allakos Inc. (ALLK) has been beaten down lately with too much selling pressure. While the stock has lost 61.4% over the past four weeks, there is light at the end of the tunnel as it is now in ...
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
SAN CARLOS, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, ...
Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024
Feb. 26, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics that target immunomodulatory receptors present on immune effector ...
Allakos Inc (ALLK) Reports Increased R&D Expenses and Net Loss in Q4
Net Loss: Allakos Inc ( NASDAQ:ALLK) reported a net loss of $62.6 million in Q4 2023, widening from $43.0 million in Q4 2022. R&D Expenses: R&D expenses rose to $53.8 million in Q4 2023, up from $35.4 ...
Allakos Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Allakos Announces a Restructuring to Focus on Development of AK006
Allakos Inc. (the Company) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today announced a restructuring to ...
Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition
Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics that target immunomodulatory receptors present on immune effector cells involved in allergy ...
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
SAN CARLOS, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory ...
Allakos Inc.: Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024
Feb. 26, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics that target immunomodulatory receptors present on immune effector ...
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
ALLAKOS INC. UNAUDITED CONDENSED BALANCE SHEETS (in thousands) December 31, 2023 2022 Assets Current assets: Cash and cash equivalents $ 66,440 $ 87,217 Investments 104,354 192,569 ...
Allakos Inc.: Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Allakos Inc. (the "Company") (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative ...
Loading the latest forecasts...